U068 What's New in Onychomycosis?
DESCRIPTION
New technology has expanded the field of onychomycosis diagnosis and treatment, while globalization has widened the spectrum of public infection. Updates on epidemiology and methods of diagnosis of onychomycosis will be reviewed, particularly as non-dermatophyte molds and mixed nail infections may be more readily detected with improving technologies. The expanding repertoire of antifungals and devices for onychomycosis will be discussed in regards to both adult and pediatric infection. Resistant species are emerging, and management strategies will be highlighted. Use of prophylactic therapy and other non-drug strategies may help reduce recurrence. Audience discussion and interaction will be encouraged.
LEARNING OBJECTIVES
Compare the traditional and newer methods for diagnosing onychomycosis
Review treatment strategies for non-dermatophyte mold onychomycosis
Recognize possible resistance and apply management strategies for resistance
SCHEDULE
8:00 AM
Introduction/What's New in the Epidemiology of Onychomycosis?
Aditya K. Gupta, MD, PhD, FAAD
8:07 AM
What's New in the Diagnosis of Onychomycosis?
Molly A. Hinshaw, MD, FAAD
8:14 AM
What's New in Pediatric Onychomycosis?
Julie Mervak, MD, FAAD
8:21 AM
What's New in the Treatment of Non-dermatophyte Mold Onychomycosis?
FRANCESCA PAMPALONI
8:31 AM
What's New in Topical Treatments and Devices for Treating Onychomycosis?
Shari Lipner, MD, PhD, FAAD
8:41 AM
What's New in Oral Therapy/Resistance in Onychomycosis?
Aditya K. Gupta, MD, PhD, FAAD
8:51 AM
Questions and Answers
DIRECTOR
Aditya K. Gupta, MD, PhD, FAAD
SPEAKERS
Molly A. Hinshaw, MD, FAAD
Shari Lipner, MD, PhD, FAAD
Julie Mervak, MD, FAAD
FRANCESCA PAMPALONI
DISCLOSURES
Aditya K. Gupta, MD, PhD, FAAD
Bausch Health – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Emblation Limited – Investigator(Grants/Research Funding); Moberg Derma – Consultant(Fees); Ortho Dermatologics – Consultant(Fees);
Molly A. Hinshaw, MD, FAAD
BiaCure Therapies Inc – Founder(Stock);
Shari Lipner, MD, PhD, FAAD
BelleTorus Corporation – Investigator(Grants/Research Funding); Moberg Pharma North America LLC – Investigator(Grants/Research Funding);
Julie Mervak, MD, FAAD
No financial relationships exist with ineligible companies.
FRANCESCA PAMPALONI
Eli Lilly – Speaker(Honoraria); Giuliani Pharma – Speaker(Honoraria); L'Oreal Italia S.P – Speaker(Honoraria);